A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors

BACKGROUND: Mechanistic target of rapamycin (mTOR) pathway is essential for the growth of gastric cancer (GC), but mTOR inhibitor everolimus was not effective for the treatment of GCs. The Cancer Genome Atlas (TCGA) researchers reported that most diffuse-type GCs were genomically stable (GS). Pathol...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Exp Clin Cancer Res
المؤلفون الرئيسيون: Fukamachi, Hiroshi, Kim, Seon-Kyu, Koh, Jiwon, Lee, Hye Seung, Sasaki, Yasushi, Yamashita, Kentaro, Nishikawaji, Taketo, Shimada, Shu, Akiyama, Yoshimitsu, Byeon, Sun-ju, Bae, Dong-Hyuck, Okuno, Keisuke, Nakagawa, Masatoshi, Tanioka, Toshiro, Inokuchi, Mikito, Kawachi, Hiroshi, Tsuchiya, Kiichiro, Kojima, Kazuyuki, Tokino, Takashi, Eishi, Yoshinobu, Kim, Yong Sung, Kim, Woo Ho, Yuasa, Yasuhito, Tanaka, Shinji
التنسيق: Artigo
اللغة:Inglês
منشور في: BioMed Central 2019
الموضوعات:
Research
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6416873/
https://ncbi.nlm.nih.gov/pubmed/30866995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1121-3
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة